Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus ® ): a randomized open-label clinical trial.

MLA

Karonova, Tatiana L., et al. “Safety and Efficacy of GP40061 Compared with Originator Insulin Glargine (Lantus ® ): A Randomized Open-Label Clinical Trial.” Journal of Comparative Effectiveness Research, vol. 9, no. 4, Mar. 2020, pp. 263–73. EBSCOhost, https://doi.org/10.2217/cer-2019-0136.

APA

Karonova, T. L., Mosikian, A. A., Mayorov, A. Y., Makarenko, I. E., Zyangirova, S. T., Afonkina, O. A., Belikova, T. M., Zalevskaya, A. G., Khokhlov, A. L., & Drai, R. V. (2020). Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus ® ): a randomized open-label clinical trial. Journal of Comparative Effectiveness Research, 9(4), 263–273. https://doi.org/10.2217/cer-2019-0136

Chicago

Karonova, Tatiana L, Anna A Mosikian, Alexander Y Mayorov, Igor E Makarenko, Svetlana T Zyangirova, Olena A Afonkina, Tatiana M Belikova, Alsu G Zalevskaya, Alexander L Khokhlov, and Roman V Drai. 2020. “Safety and Efficacy of GP40061 Compared with Originator Insulin Glargine (Lantus ® ): A Randomized Open-Label Clinical Trial.” Journal of Comparative Effectiveness Research 9 (4): 263–73. doi:10.2217/cer-2019-0136.